Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. Their research and development efforts are centered on creating therapies that selectively target and inhibit cancer-driving proteins, particularly those within the RAS and mTOR signaling pathways. They aim to transform cancer treatment by designing drugs against previously intractable targets. Their pipeline includes multiple programs in various stages of clinical development, leveraging their proprietary TRIPOD platform for drug discovery.
Serves as the primary hub for research and development, corporate operations, clinical development, and strategic planning for the company's oncology programs.
State-of-the-art laboratory facilities designed for advanced cancer research, including drug discovery and translational medicine. Collaborative workspaces fostering innovation among scientific and corporate teams.
A science-driven, innovative, and collaborative environment. Employees are typically mission-focused on advancing cancer treatments. The culture emphasizes teamwork, scientific rigor, and a fast-paced approach to drug development.
Located in the San Francisco Bay Area, a prominent global hub for biotechnology and pharmaceutical innovation, providing access to a rich talent pool, research institutions, and venture capital.
While its primary physical offices are in the United States (Redwood City, CA and Cambridge, MA), Revolution Medicines operates with a global perspective, particularly in its clinical trial activities. The company conducts clinical studies across North America, Europe, and Asia-Pacific to evaluate its investigational therapies in diverse patient populations. Their drug development programs aim to address cancer, a global health issue.
700 Saginaw Drive
Redwood City
CA
USA
Address: One Kendall Square, Building 1400W, Suite 14-102, Cambridge, MA 02139
Facilitates engagement with the Boston/Cambridge biotech hub, supporting research collaborations, clinical trial operations, and access to key opinion leaders in oncology.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Revolution Medicines' leadership includes:
Revolution Medicines has been backed by several prominent investors over the years, including:
In the past year, Revolution Medicines has seen key appointments strengthening its leadership, notably with Jack F. Anders taking on the CFO role and Jeff P. Winton joining as Chief People and Culture Officer. There have been no major publicly announced executive departures.
Discover the tools Revolution Medicines uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Revolution Medicines most commonly uses the email format combining the first initial and last name. Other formats might exist but are less common.
flast@revmed.com
Format
jdoe@revmed.com
Example
85%
Success rate
GlobeNewswire • July 16, 2024
Revolution Medicines announced initial clinical data from the Phase 1/1b trial of RMC-6236 in patients with KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC). The data show encouraging anti-tumor activity and a manageable safety profile....more
GlobeNewswire • May 21, 2024
Revolution Medicines announced it would present preclinical data for RMC-9805, its first-in-class, mutant-selective PI3Kα(ON) inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights its differentiated mechanism and potential for treating PIK3CA-mutant cancers....more
GlobeNewswire • May 7, 2024
Revolution Medicines provided a corporate update and reported financial results for the first quarter ended March 31, 2024. The company highlighted progress across its pipeline of RAS(ON) inhibitors and other oncology programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Revolution Medicines, are just a search away.